Queen's Award Received in 2021 ISO 9001 Certified Delivered over 1,000,000 bio-reagents to life science researchers Trusted by Life Science Communities
Cart summary

You have no items in your shopping cart.

Quizartinib

SKU: orb1306579
FeaturedFeatured Product

Description

Quizartinib (AC220) is a potent and selective oral type II FLT3 inhibitor, effective against both FLT3-WT and FLT3-ITD mutations. It induces apoptosis in leukemic cells and has demonstrated significant anti-tumor activity in preclinical models of acute myeloid leukemia (AML), supporting its investigation in both in vitro and in vivo research.

Research Area

Pharmacology & Drug Discovery

Images & Validation

−
Quizartinib

Key Properties

−
CAS Number950769-58-1
MW560.67
Purity>98%
FormulaC29H32N6O4S
SMILESCC(C)(C)c1cc(NC(=O)Nc2ccc(cc2)-c2cn3c(n2)sc2cc(OCCN4CCOCC4)ccc32)no1
TargetKinase
SolubilitySoluble in DMSO (up to at least 25 mg/ml)

Bioactivity

−
Target IC50
FLT3:1.6 nM (Kd, cell free)
In Vivo
Treatment with AC220 at 10 mg/kg resulted in rapid and complete regression of tumors in all animals, and no tumor regrowth was observed during the 60-day posttreatment observation period. AC220 prolonged survival in a dose-dependent manner. At 10 mg/kg, 80% of animals treated survived until the study was terminated on day 172, 119 days after discontinuation of treatment, corresponding to at least a 250% increase in life span (ILS). At the time the study was terminated the animals did not exhibit any signs of disease. At 1 mg/kg a significant increase in the mean survival time was observed, to 77 days. At the lowest dose tested of 0.1 mg/kg, a marginal 10% ILS relative to vehicle was observed . At 1 mg/kg of AC220, tumor growth was completely inhibited during the dosing period, after which growth resumed. At 3 and 10 mg/kg of AC220, tumors regressed almost completely and the tumor volume stayed suppressed after dosing was halted. At 3 mg/kg, tumors appeared to regrow after day 49 (21 days post last dose), while there was no sign of tumor regrowth until day 60 (32 days post last dose) in the animals treated with 10 mg/kg of AC220 .
Read more...
In Vitro
The highest affinity target identified for Quizartinib (AC220) was FLT3. The only other kinases with binding constants within 10-fold that for FLT3 were the closely related receptor tyrosine kinases (RTKs) KIT, PDGFRA, PDGFRB, RET, and CSF1R, and only 4 additional kinases, also related RTKs (FLT1, FLT4, DDR1, VEGFR2), bound with Kds within 100-fold of that for FLT3. In primary cells, treatment with AC220 for 1 hour inhibited FLT3 autophosphorylation (IC50: 2 nM), comparable with the activity observed in the MV4-11 cell line. The primary cells were sensitive to AC220 (IC50: 0.3 nM), again comparable with the activity observed in the MV4-11 cell line . It inhibits the proliferation of the human leukemia cell line MV4-11, which harbors a homozygous FLT3-ITD mutation, with an IC50 value of 0.56 nM .
Read more...
Cell Research
MV4-11 and RS4;11 cells were cultured in Iscove media with 10% fetal bovine serum (FBS) and RPMI complete with 10% FBS, respectively. For proliferation assays, cells were cultured overnight in low serum media (0.5% FBS), then seeded in a 96-well plate at 40 000 cells per well. Inhibitors were added to the cells and incubated at 37°C for 72 hours. Cell viability was measured using the Cell Titer-Blue Cell Viability Assay. To measure inhibition of FLT3 autophosphorylation, cells were cultured in low serum media (0.5% FBS) overnight and seeded at a density of 400 000 cells per well in a 96-well plate the following day. The cells were incubated with inhibitors for 2 hours at 37°C. To induce FLT3 autophosphorylation in RS4;11 cells, 100 ng/mL FLT3 ligand was added for 15 minutes after the 2-hour compound incubation. Cell lysates were prepared and incubated in 96-well plates pre-coated with a total FLT3 capture antibody. The coated plates were incubated with either a biotinylated antibody against FLT3 to detect total FLT3 or an antibody against phosphotyrosines to detect FLT3 autophosphorylation. In both cases, a SULFO-tagged streptavidin secondary antibody was used for electrochemiluminescence detection on the Meso Scale Discovery platform .
Read more...
Animal Research
The model was performed according to published procedures.20 For intravenous bone marrow engraftment, nonobese diabetic/severe combined immunodeficient mice were acclimated for 2 weeks before pretreatment with 150 mg/kg cyclophosphamide delivered intraperitoneally once a day for 2 days. After a 48-hour rest period, animals were given an intravenous injection of 5 × 10^6 MV4-11 cells into the tail vein. AC220 was formulated and delivered as described for pharmacokinetic studies .
Read more...

Storage & Handling

−
Storage-20°C
Expiration Date12 months from date of receipt.
DisclaimerFor research use only

Alternative Names

−
AC220

Similar Products

−
  • Plogosertib

    Plogosertib [orb1738081]

    99.85%

    1137212-79-3

    616.797

    C34H48N8O3

    5 mg, 10 mg, 1 mg, 1 ml x 10 mM (in DMSO), 25 mg, 50 mg, 100 mg
  • Desmorpholinyl Quizartinib-PEG2-COOH

    Desmorpholinyl Quizartinib-PEG2-COOH [orb1691031]

    2292116-14-2

    607.68

    C30H33N5O7S

    50 mg, 100 mg
  • Quizartinib HCl

    Quizartinib HCl [orb1738080]

    1132827-21-4

    633.59

    C29H34Cl2N6O4S

    50 mg, 100 mg, 25 mg
  • MRX-2843

    MRX-2843 [orb1220102]

    >98% (HPLC)

    1429882-07-4

    488.67

    C29H40N6O

    200 mg, 10 mg, 1 g, 500 mg, 25 mg, 50 mg, 100 mg, 5 mg
  • Quizartinib

    Quizartinib [orb1223539]

    >98% (HPLC)

    950769-58-1

    560.6672

    C29H32N6O4S

    1 g, 500 mg, 200 mg, 5 mg, 10 mg, 50 mg, 100 mg, 25 mg
Quality Guarantee

Quality Guarantee

Explore bioreagents carefree to elevate your research. All our products are rigorously tested for performance. If a product does not perform as described on its datasheet, our scientific support team will provide expert troubleshooting, a prompt replacement, or a refund. For full details, please see our Terms & Conditions and Buying Guide. Contact us at support@biorbyt.com.

Compound Identifiers

PubChem CID
24889392 ↗

Key Properties

−
No computed properties available.

Documents Download

Datasheet
Product Information
Download

Request a Document

Protocol Information

Find More Protocols

Quizartinib (orb1306579)

  • Star
  • Star
  • Star
  • Star
  • Star
  • 0.0
Based on 0 reviews

Participating in our Biorbyt product reviews program enables you to support fellow scientists by sharing your firsthand experience with our products.

Login to Submit a Review

No reviews yet

Login to review

Step 1: Enter information below

(Recommended: An additional animal making an allowance for loss during the experiment)

Step 2: Enter the in vivo formulation

(This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO +
%+
% Tween 80 +
%

Available Sizes

Select a size below

5 mg
$ 170.00
25 mg
$ 260.00
DispatchUsually dispatched within 3-5 working days
Bulk Enquiry
Need technical support? Find your Distributor Return and Tax Policy

Email

info@biorbyt.com

UK Office

+44 (0)1223 859353

US Office

+1 (415) 906-5211

CN Office

+86 (27)-87663101

Distributors

biorbyt.com/distributor